Advanced

Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation.

Uller, Lena LU ; Mathiesen, Jesper Mosolff; Alenmyr, Lisa LU ; Korsgren, Magnus LU ; Ulven, Trond; Hogberg, Thomas; Andersson, Gunnar; Persson, Carl LU and Kostenis, Evi (2007) In Respiratory Research 8:16.
Abstract
Background: Mast cell-derived prostaglandin D-2 (PGD(2)), may contribute to eosinophilic inflammation and mucus production in allergic asthma. Chemoattractant receptor homologous molecule expressed on TH2 cells (CRTH2), a high affinity receptor for prostaglandin D-2, mediates trafficking of TH2-cells, mast cells, and eosinophils to inflammatory sites, and has recently attracted interest as target for treatment of allergic airway diseases. The present study involving mice explores the specificity of CRTH2 antagonism of TM30089, which is structurally closely related to the dual TP/CRTH2 antagonist ramatroban, and compares the ability of ramatroban and TM30089 to inhibit asthma-like pathology. Methods: Affinity for and antagonistic potency of... (More)
Background: Mast cell-derived prostaglandin D-2 (PGD(2)), may contribute to eosinophilic inflammation and mucus production in allergic asthma. Chemoattractant receptor homologous molecule expressed on TH2 cells (CRTH2), a high affinity receptor for prostaglandin D-2, mediates trafficking of TH2-cells, mast cells, and eosinophils to inflammatory sites, and has recently attracted interest as target for treatment of allergic airway diseases. The present study involving mice explores the specificity of CRTH2 antagonism of TM30089, which is structurally closely related to the dual TP/CRTH2 antagonist ramatroban, and compares the ability of ramatroban and TM30089 to inhibit asthma-like pathology. Methods: Affinity for and antagonistic potency of TM30089 on many mouse receptors including thromboxane A(2) receptor mTP, CRTH2 receptor, and selected anaphylatoxin and chemokines receptors were determined in recombinant expression systems in vitro. In vivo effects of TM30089 and ramatroban on tissue eosinophilia and mucus cell histopathology were examined in a mouse asthma model. Results: TM30089, displayed high selectivity for and antagonistic potency on mouse CRTH2 but lacked affinity to TP and many other receptors including the related anaphylatoxin C3a and C5a receptors, selected chemokine receptors and the cyclooxygenase isoforms 1 and 2 which are all recognized players in allergic diseases. Furthermore, TM30089 and ramatroban, the latter used as a reference herein, similarly inhibited asthma pathology in vivo by reducing peribronchial eosinophilia and mucus cell hyperplasia. Conclusion: This is the first report to demonstrate anti-allergic efficacy in vivo of a highly selective small molecule CRTH2 antagonist. Our data suggest that CRTH2 antagonism alone is effective in mouse allergic airway inflammation even to the extent that this mechanism can explain the efficacy of ramatroban. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Disease Models, Cultured, Asthma: immunology, Bronchoalveolar Lavage Fluid: cytology, Bronchial Hyperreactivity: physiopathology, Bronchial Hyperreactivity: immunology, Asthma: pathology, Enzyme-Linked Immunosorbent Assay, Animal, Cells, Carbazoles: pharmacology, Female, Prostaglandin Antagonists: pharmacology, Inbred BALB C, Mice, Inflammation: pathology, Inflammation: drug therapy, Pulmonary Eosinophilia: immunology, Immunization, Animals, Pulmonary Eosinophilia: pathology, Radioligand Assay, Receptors, Immunologic: antagonists & inhibitors, Prostaglandin: antagonists & inhibitors, Sensitivity and Specificity, Sulfonamides: pharmacology, Asthma: drug therapy
in
Respiratory Research
volume
8:16
publisher
BioMed Central
external identifiers
  • wos:000244744600001
  • scopus:69249240524
ISSN
1465-9921
DOI
10.1186/1465-9921-8-16
language
English
LU publication?
yes
id
dfa0c38a-8dc3-431c-a0fb-0f0b559cd2a6 (old id 166969)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17328802&dopt=Abstract
date added to LUP
2007-07-06 09:36:31
date last changed
2017-11-05 03:31:23
@article{dfa0c38a-8dc3-431c-a0fb-0f0b559cd2a6,
  abstract     = {Background: Mast cell-derived prostaglandin D-2 (PGD(2)), may contribute to eosinophilic inflammation and mucus production in allergic asthma. Chemoattractant receptor homologous molecule expressed on TH2 cells (CRTH2), a high affinity receptor for prostaglandin D-2, mediates trafficking of TH2-cells, mast cells, and eosinophils to inflammatory sites, and has recently attracted interest as target for treatment of allergic airway diseases. The present study involving mice explores the specificity of CRTH2 antagonism of TM30089, which is structurally closely related to the dual TP/CRTH2 antagonist ramatroban, and compares the ability of ramatroban and TM30089 to inhibit asthma-like pathology. Methods: Affinity for and antagonistic potency of TM30089 on many mouse receptors including thromboxane A(2) receptor mTP, CRTH2 receptor, and selected anaphylatoxin and chemokines receptors were determined in recombinant expression systems in vitro. In vivo effects of TM30089 and ramatroban on tissue eosinophilia and mucus cell histopathology were examined in a mouse asthma model. Results: TM30089, displayed high selectivity for and antagonistic potency on mouse CRTH2 but lacked affinity to TP and many other receptors including the related anaphylatoxin C3a and C5a receptors, selected chemokine receptors and the cyclooxygenase isoforms 1 and 2 which are all recognized players in allergic diseases. Furthermore, TM30089 and ramatroban, the latter used as a reference herein, similarly inhibited asthma pathology in vivo by reducing peribronchial eosinophilia and mucus cell hyperplasia. Conclusion: This is the first report to demonstrate anti-allergic efficacy in vivo of a highly selective small molecule CRTH2 antagonist. Our data suggest that CRTH2 antagonism alone is effective in mouse allergic airway inflammation even to the extent that this mechanism can explain the efficacy of ramatroban.},
  author       = {Uller, Lena and Mathiesen, Jesper Mosolff and Alenmyr, Lisa and Korsgren, Magnus and Ulven, Trond and Hogberg, Thomas and Andersson, Gunnar and Persson, Carl and Kostenis, Evi},
  issn         = {1465-9921},
  keyword      = {Disease Models,Cultured,Asthma: immunology,Bronchoalveolar Lavage Fluid: cytology,Bronchial Hyperreactivity: physiopathology,Bronchial Hyperreactivity: immunology,Asthma: pathology,Enzyme-Linked Immunosorbent Assay,Animal,Cells,Carbazoles: pharmacology,Female,Prostaglandin Antagonists: pharmacology,Inbred BALB C,Mice,Inflammation: pathology,Inflammation: drug therapy,Pulmonary Eosinophilia: immunology,Immunization,Animals,Pulmonary Eosinophilia: pathology,Radioligand Assay,Receptors,Immunologic: antagonists & inhibitors,Prostaglandin: antagonists & inhibitors,Sensitivity and Specificity,Sulfonamides: pharmacology,Asthma: drug therapy},
  language     = {eng},
  publisher    = {BioMed Central},
  series       = {Respiratory Research},
  title        = {Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation.},
  url          = {http://dx.doi.org/10.1186/1465-9921-8-16},
  volume       = {8:16},
  year         = {2007},
}